The FDA approval of GLP-1 receptor agonist (Liraglutide) for use in children

Authors: BACHA, FIDA - Children'S Nutrition Research Center (CNRC)

Submitted to: The Lancet Global Health
Publication Type: Other
Publication Acceptance Date: 7/22/2019
Publication Date: 7/22/2019
Citation: Bacha, F. 2019. The FDA approval of GLP-1 receptor agonist (Liraglutide) for use in children. The Lancet Global Health. 3(9):595-597. https://doi.org/10.1016/S2352-4642(19)30236-6.
DOI: https://doi.org/10.1016/S2352-4642(19)30236-6

Interpretive Summary:

Technical Abstract: The incidence of type 2 diabetes in children and adolescents aged 10–19 years increased in the 2002–12 period, and the burden of the disease is projected to continue to increase over the next 30 years. Until July, 2019, the approved pharmaceutical options for the treatment of type 2 diabetes in children and adolescents were limited to metformin and insulin. However, these therapies have proved to be less effective in children and adolescents than in adults with the disease. The recent US Food and Drug Administration (FDA) approval of liraglutide for use in paediatric type 2 diabetes begins to address an unmet need in paediatric diabetes therapy.